|DB01007||Tioconazole||For the local treatment of vulvovaginal candidiasis (moniliasis).|
|DB01110||Miconazole||For topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.|
|DB04794||Bifonazole||Used for the treatment of various topical fungal infections, including athlete's foot (tinea pedis).|
|DB06820||Sulconazole||Sulconazole solution 1.0% is indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete’s foot).|
|DB08933||Luliconazole||Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis.
|DB09040||Efinaconazole||Indicated in the treatment of fungal infection of the nail, known as onychomycosis.|
|DB00196||Fluconazole||**Fluconazole can be administered in the treatment of the following fungal infections**:
Vaginal candidiasis (vaginal yeast infections due to Candida) [FDA label]
Oropharyngeal and esophageal candidiasis [FDA label]
Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia [FDA label]
Cryptococcal meningitis [FDA label].
**Fungal infection prophylaxis**: this drug can be used in the prophylaxis of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy [FDA label]
**A note on laboratory testing**:
Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) are recommended to be obtained prior to therapy to isolate and identify the causative organism(s). Therapy may be initiated before the results of the cultures and other laboratory studies are returned; however, once these results become available, therapy must be adjusted accordingly [FDA label].
|DB00239||Oxiconazole||For treatment of dermal fungal infection.|
Clotrimazole topical cream is indicated for the topical treatment of the following dermal infections [F3088], [F3121]:
Tinea pedis, tinea cruris, and tinea corporis due to _Trichophyton rubrum_, _Trichophyton mentagrophytes_, _Epidermophyton floccosum_
Candidiasis due to _Candida albicans_
Tinea versicolor due to _Malassezia furfur_
Diaper rash infected by _Candida albicans_
In some preparations, clotrimazole may be combined with betamethasone dipropionate, a corticosteroid [F3121].
The oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis [FDA label]. It is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation [FDA label]. Troche preparations are not indicated for the treatment of any systemic mycoses [FDA label].|
|DB00730||Thiabendazole||For the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.|
|DB01026||Ketoconazole||For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.|
|DB01127||Econazole||For topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.|
|DB01153||Sertaconazole||For the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.|